ES2194213T3 - Beta-carbolinas-4- sustituidas en calidad de inmunomoduladores. - Google Patents

Beta-carbolinas-4- sustituidas en calidad de inmunomoduladores.

Info

Publication number
ES2194213T3
ES2194213T3 ES97938122T ES97938122T ES2194213T3 ES 2194213 T3 ES2194213 T3 ES 2194213T3 ES 97938122 T ES97938122 T ES 97938122T ES 97938122 T ES97938122 T ES 97938122T ES 2194213 T3 ES2194213 T3 ES 2194213T3
Authority
ES
Spain
Prior art keywords
replaced
carbolins
carbolinas
immunomodulators
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97938122T
Other languages
English (en)
Inventor
Karl D Hargrave
Clara K Miao
Thomas P Parks
Ian F Potocki
Roger J Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharmaceuticals Inc filed Critical BOEHRINGER INGELHEIM PHARMA
Application granted granted Critical
Publication of ES2194213T3 publication Critical patent/ES2194213T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

LA INVENCION SE REFIERE A BE - CARBOLINAS SUSTITUIDAS EN POSICION 4 Y A ANALOGOS DE CARBOLINA, QUE INHIBEN LA ENTRADA DE CA 2+ Y LA PRODUCCION DE INTERLEUQUINA-2 (IL-2). LAS BE CARBOLINAS SUSTITUIDAS EN POSICION 4 Y LOS ANALOGOS DE BE CARBOLINA DE LA PRESENTE INVENCION SE REPRESENTAN MEDIANTE LA FORMULA (I), DONDE Q, N, R, R'', R'''' Y R 1 - R 4 SON TAL Y COMO SE LOS DEFINE EN LA DESCRIPCION. LA INVENCION SE REFIERE ASIMISMO A PROCEDIMIENTOS DE PRODUCCION DE BE - CARBOL INAS. DEBIDO A SUS PROPIEDADES INMUNOMODULADORAS SELECTIVAS, LOS COMPUESTOS Y COMPOSICIONES FARMACEUTICAS DE LA INVENCION, SON ESPECIALMENTE ADECUADOS PARA EVITAR Y TRATAR ALTERACIONES INMUNITARIAS, INCLUYENDO ENFERMEDADES AUTOINMUNES, ENFERMEDAD INFLAMATORIA, RECHAZO DE TRASPLANTE DE ORGANOS Y OTRAS ALTERACIONES ASOCIADAS CON LA RESPUESTA INMUNE MEDIADA POR IL-2.
ES97938122T 1996-08-09 1997-08-08 Beta-carbolinas-4- sustituidas en calidad de inmunomoduladores. Expired - Lifetime ES2194213T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2365096P 1996-08-09 1996-08-09

Publications (1)

Publication Number Publication Date
ES2194213T3 true ES2194213T3 (es) 2003-11-16

Family

ID=21816410

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97938122T Expired - Lifetime ES2194213T3 (es) 1996-08-09 1997-08-08 Beta-carbolinas-4- sustituidas en calidad de inmunomoduladores.

Country Status (10)

Country Link
US (1) US6093723A (es)
EP (1) EP0923581B1 (es)
JP (1) JP2000516231A (es)
AT (1) ATE240955T1 (es)
CA (1) CA2262796C (es)
DE (1) DE69722220T2 (es)
DK (1) DK0923581T3 (es)
ES (1) ES2194213T3 (es)
PT (1) PT923581E (es)
WO (1) WO1998006719A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047510A2 (en) * 1999-12-29 2001-07-05 Glaxo Group Limited Methods and compositions related to modulators of annexin and cartilage homeostasis
NZ521386A (en) * 2000-03-15 2004-06-25 Aventis Pharma Gmbh Substituted beta-carbolines with lkB-kinase inhibiting activity
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
US6379900B1 (en) 2000-05-09 2002-04-30 Conceptual Mindworks, Inc. Compositions and methods of use of 8-nitroguanine
US20030045541A1 (en) * 2001-07-23 2003-03-06 Christopher Bruckner GABA-Receptor modulators with NMDA-Antagonistic activity
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤
JP5320083B2 (ja) * 2009-01-13 2013-10-23 坂元醸造株式会社 潰瘍性大腸炎治療薬
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
CA2763479A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Processes for the preparation of substituted tetrahydro beta-carbolines
TWI574961B (zh) 2009-05-27 2017-03-21 Ｐｔｃ治療公司 治療癌症及非腫瘤病症之方法
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2011248579A1 (en) 2010-04-27 2012-11-29 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR101840313B1 (ko) * 2011-02-14 2018-03-21 에스에프씨 주식회사 피리딘 유도체 화합물 및 이를 포함하는 유기전계발광소자
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8871778B2 (en) * 2012-01-20 2014-10-28 Genosco Substituted pyrimidine compounds and their use as SYK inhibitors
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
DK3778595T3 (da) 2015-02-27 2021-10-18 Calcimedica Inc Pancreatitisbehandling
EP3331525B1 (en) 2015-08-07 2020-10-07 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ194747A (en) * 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
SU859889A1 (ru) * 1980-01-17 1981-08-30 Читинский Медицинский Институт Способ количественного определени 1-метил-4-(N-метилпирролидил-1)- -карболин гидрохлорида
DE3240514A1 (de) * 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
WO1991013627A1 (en) * 1990-03-14 1991-09-19 The Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
DK0610744T3 (da) * 1993-02-09 1999-07-19 Bayer Ag Sulfonamidaminomethylenderivater som immunosuppressive stoffer
JPH07112918A (ja) * 1993-10-15 1995-05-02 Pola Chem Ind Inc 育毛剤及びこれを含有する頭髪用化粧料
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate

Also Published As

Publication number Publication date
DE69722220D1 (de) 2003-06-26
WO1998006719A1 (en) 1998-02-19
JP2000516231A (ja) 2000-12-05
ATE240955T1 (de) 2003-06-15
PT923581E (pt) 2003-10-31
US6093723A (en) 2000-07-25
EP0923581A1 (en) 1999-06-23
DE69722220T2 (de) 2004-02-19
CA2262796A1 (en) 1998-02-19
CA2262796C (en) 2006-10-31
DK0923581T3 (da) 2003-08-04
EP0923581B1 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
ES2194213T3 (es) Beta-carbolinas-4- sustituidas en calidad de inmunomoduladores.
AR015103A1 (es) Compuestos derivados de 6,6-heterobiciclicos sustituidos y composiciones que los contienen e intermediarios
AR028985A1 (es) Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
ES2196377T3 (es) Derivados de naftiridina.
ES2064310T3 (es) Procedimiento para preparar compuestos de imidazopiridina.
PA8591701A1 (es) Derivados de pirrolopirimidina
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
HN1997000052A (es) Nuevas 4(3h)--quinazolinas 2,3-disustituidas
GT199900131A (es) Derivados del acido hidroxi-pipecolato hidroxamico.
HN1998000074A (es) Derivados de macrolidos c-4 sustituidos
PA8582701A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
PA8432901A1 (es) Compuestos de piridilpirrol
CL2004000848A1 (es) Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
ES2072263T3 (es) Derivados de 4-aminopiridina.
UY28317A1 (es) Compuestos útiles para el tratamiento de enfermedades
ES2115904T3 (es) Derivados amino ramificados del tiazol, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ZA806399B (en) New 2-hydroxyalkyl-3,4,5-trihydroxypiperidine compounds, their production and their medicinal use
AR050956A1 (es) Derivados de bencimidazol; sintesis de los mismos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por ligandos del receptor cb1.
GT200100209A (es) Derivados puente de piperazina.
ES2151716T3 (es) Derivados peptidos.
NZ241099A (en) Difluorostatone analogues and derivatives and pharmaceutical compositions
ES2177671T3 (es) Benzamida enterocinetica.